Drug metabolism by escherichia coli expressing human cytochromes P450

Nature Biotechnology

Volumn 15, Issue 8, 1997, Pages 784-788

  Parikh, Asit ^a   Gillam, Elizabeth M J ^b   Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Bicistronic constructs; Cytochrome P450; Drug metabolism; NADPH cytochrome P450

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; ETHOXYRESORUFIN; PHENACETIN; TESTOSTERONE; TOLBUTAMIDE;

ARTICLE; BACTERIAL METABOLISM; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; ELECTRON TRANSPORT; ENZYME INDUCTION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; HUMAN; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL;

CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ESCHERICHIA COLI; HUMANS; NADH, NADPH OXIDOREDUCTASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; OPERON; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MAMMALIA;

EID: 0030843652     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0897-784     Document Type: Article

References (41)

1. 2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli. J. Biol. Chem. 266:7321-7324.
2. Barnes, H.J., Arlotto, M.P., and Waterman, M.R. 1991. Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc. Natl. Acad. Sci. USA 88:5597-5601.
3. Josephy, P.D., DeBruin, L.S., Lord, H.L., Oak, J., Evans, D.H., Guo, Z., et al. 1995. Bioactivation of aromatic amines by recombinant human cytochrome P450 1A2 expressed in bacteria: a substitute for mammalian tissue preparations in mutagenicity testing. Cancer Res. 55:799-802.
4. Guengerich, F.P. 1995. Human cytochrome P450 enzymes, pp. 473-535 in Cytochrome P450. Ortiz de Montellano, PR. (ed.) Plenum Press, New York, NY.
5. Jenkins, CM. and Waterman, M.R. 1994. Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities. J. Biol. Chem. 269:27401-27408.
6. Yamazaki, H., Ueng, Y-E, Shimada, T., and Guengerich, h.R 1995. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of iron-sulfur proteins and oxygen surrogates. Biochemistry 34:8380-8389.
7. Murakami, H., Yabusaki, Y, Sakaki, T., Shibata, M., and Ohkawa, H. 1987. A genetically engineered P450 monooxygenase: construction of the functional fused enzyme between rat cytochrome P450c and NADPH-cytochrome P450 reductase. DNA 6:189-197.
8. Shet, M.S., Fisher, C.W., Holmans, PL, and Estabrook, R.W. 1993. Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc. Natl. Acad. Sci. USA 90:11748-11752.
9. Chun, Y-J., Shimada, T., and Guengerich, F.P. 1996. Construction of a human cytochrome P450 1A1:rat NADPH-P450 reductase fusion protein cDNA, expression in Escherichia coli, purification, and catalytic properties of the enzyme in bacterial cells and after purification. Arch. Biochem. Biophys. 330:48-58.
10. Parikh, A. and Guengerich, F.P. 1997. Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:NADPH-cytochrome P450 reductase fusion protein. Protein Express. Purif. 9:346-354.
11. Metz, M.Z., Matsumoto, L, Winters, K.A., Doroshow, J.H., and Kane, S.E. 1996. Bicistronic and two-gene retroviral vectors for using MDR1 as a selectable marker and a therapeutic gene. Virology 217:230-241.
12. Lieschke, G.J., Rao, P.K., Gately, M.K., and Mulligan, R.C. 1997. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nature Biotechnology 15:35-40.
13. Shi, Y., Brown, E.D., and Walsh, C.T. 1994. Expression of recombinant human casein kinase II and recombinant heat shock protein 90 in Escherichia coli and characterization of their interactions. Proc. Natl. Acad. Sci. USA 91:2767-2771.
14. Tarragona-Fiol, A., Taylorson, C.J., Ward, J.M., and Rabin, B.R. 1992. Production of mature bovine ribonuclease in Escherichia coli. Gene 118:239-245.
15. Dong, J. and Porter, T.D. 1996. Coexpression of mammalian cytochrome P450 and reductase in Escherichia coli. Arch. Biochem. Biophys. 327:254-259.
16. Blake, J.A.R., Pritchard, M., Ding, S., Smith, G.C.M., Burchell, B., Wolf, C.R., and Friedberg, T. 1996. Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett. 397:210-214.
17. Shet, M.S., Fisher, C.W., and Estabrook, R.W. 1997. The function of recombinant cytochrome P450S in intact Escherichia coli cells: the l7α-hydroxylation of progesterone and pregnenolone by P450c17. Arch. Biochem. Biophys. 339:218-225.
18. Guengerich, F.P., Gillam, E.M.J., and Shimada, T. 1996. New applications of bacterial systems to problems in toxicology. Crit. Rev. Toxicol. 26:551-583.
19. Guengerich, RR, Martin, M.V., Guo, Z., and Chun, Y-J. 1996. Purification of recombinant human cytochrome P450 enzymes expressed in bacteria. Methods Enzymol. 272:35-44.
20. Omura, T. and Sato, R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:2370-2378.
21. Choc, M.G., Webster, D.A., and Caughey, W.S. 1982. Oxygenated intermediate and carbonyl species of cytochrome о (Vitreoscilla): characterization by infrared spectroscopy. J. Biol. Chem. 257:865-869.
22. Guengerich, F.P., Wang, P., and Mason, P.S. 1981. Immunological comparison of rat, rabbit, and human liver NADPH-cytochrome P-450 reductases. Biochemistry 20: 2379-2385.
23. Porter, T.D., Wilson, T.E., and Kasper, C.B. 1987. Expression of a functional 78,000 dalton mammalian flavoprotein, NADPH-cytochrome P-450 oxidoreductase, in Escherichia coli. Arch. Biochem. Biophys. 254:353-367.
24. Shen, A.L., Porter, T.D., Wilson, T.E., and Kasper, C.B. 1989. Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J. Biol. Chem. 264:7584-7589.
25. Schenkman, J.B., Remmer, H., and Estabrook, R.W. 1967. Spectral studies of drug interaction with hepatic microsomal cytochrome P-450. Mol. Pharmacol. 3:113-123.
26. Riley, M. and Labedan, B. 1996. Escherichia coli gene products: physiological functions and common ancestries, pp. 2118-2202 in Escherichia coli and Salmonella. Neidhardt, F.C. et al. (eds.) American Society of Microbiology, Washington, D.C.
27. Gold, L. 1991. Expression of heterologous proteins in Escherichia coli. Methods Enzymol. 185:11-14.
28. Olins, P.O. and Rangwala, S.H. 1990. Vector for enhanced translation of foreign genes in Escherichia coli. Methods Enzymol. 185, 115-119.
29. Schoner, B.E., Belagaje, R.M., and Schoner, R.G. 1990. Enhanced translational efficiency with two-cistron expression system. Methods Enzymol. 185, 94-103.
30. Sambrook, J., Fritsch, E. F., and Maniatis, T. 1989. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
31. Burke, M.D. and Mayer, R.T. 1983. Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkylethers (alkoxyresorufins). Chem.-Biol. Interact. 45:243-258.
32. Burke, M.D. and Mayer, R.T. 1975. Inherent specificities of purified cytochromes P-450 and P-448 toward biphenyl hydroxylation and ethoxyresorufin deethylation. Drug Metab. Dispos. 3:245-253.
33. Distlerath, L.M., Reilly, P.E.B., Martin, M.V., Davis, G.G., Wilkinson, G.R., and Guengerich, F.P. 1985. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260:9057-9067.
34. Larrey, D., Distlerath, L.M., Dannan, G.A., Wilkinson, G.R., and Guengerich, F.P 1984. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 23:2787-2795.
35. Knodell, R.G., Hall, S.D., Wilkinson, G.R., and Guengerich, F.P. 1987. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241:1112-1119.
36. Gillam, E.M.J., Guo, Z., Martin, M.V., Jenkins, C.M., and Guengerich, F.P. 1995. Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch. Biochem. Biophys. 319:540-550.
37. -3, J. Biol. Chem. 265:4233-4239.
38. 4. Nature 227:680-685.
39. Guengerich, F.P. 1994. Analysis and characterization of enzymes, pp 1259-1313 in Principles and Methods of Toxicology. Hayes, AW. (ed.) Raven Press, Ltd., New York, NY
40. Wray, W., Boulikas, T, Wray, V.P., and Hancock, R. 1981. Silver staining of proteins in Polyacrylamide gels. Anal. Biochem. 118:197-203.
41. Yasukochi, Y. and Masters, B.S.S. 1976. Some properties of a detergent-solubilized NADPH-cytochrome с (cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem. 251:5337-5344.